NEJM evidence 2022 Jun 06
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
ABSTRACT
Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional therapy. Median OS increased significantly by 2.5 months (16.4 vs. 13.8) with single-dose tremelimumab plus durvalumab treatment every 4 weeks versus sorafenib alone.
Related Questions
New answer by Medical Oncologist at NYU Grossman School of Medicine (April 30, 2024)
I use a range of factors, discussed here and here, when deciding between atezo/bev and STRIDE regimens in my patients with advanced HCC.Summarily, both regimens demonstrated c...